| 摘要 |
FIELD: medicine; pharmacy. ^ SUBSTANCE: invention refers to antibodies developing modulated binding with FcgammaR, and antibody contains at least one amino acid substitute in Fc-zone of original Fc-polypeptide, specifically of human origin. Mentioned modulation is expressed in affinity increase of mentioned antibody relative to FcgammaR. Various antibody versions are designed, for example those developing modulated effector function, those containing of aglyconized Fc-variant of original Fc-polypeptide and those characterized by improved binding affinity to ligand Fc in comparison to aglyconized form of original Fc-polypeptide. Obtained antibodies are used in pharmaceutical formulation containing modulated binding with FcgammaR, and method of mammal medical treatment of relevant abnormalities. ^ EFFECT: improvement of antibody affinity. ^ 67 cl, 44 dwg, 66 tbl, 12 ex |
